{"id":"pegasys-roche","safety":{"commonSideEffects":[{"rate":"50-80","effect":"Flu-like symptoms (fever, fatigue, myalgia)"},{"rate":"30-50","effect":"Headache"},{"rate":"20-40","effect":"Neutropenia"},{"rate":"10-20","effect":"Thrombocytopenia"},{"rate":"10-30","effect":"Depression / mood changes"},{"rate":"10-20","effect":"Alopecia"},{"rate":"10-15","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL5941924","moleculeType":null,"molecularWeight":"314.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pegasys works by binding to interferon alfa receptors on cell surfaces, triggering JAK-STAT signaling pathways that upregulate antiviral and antiproliferative genes. This leads to enhanced natural killer cell and cytotoxic T-lymphocyte activity, reduced viral protein synthesis, and inhibition of cell division. The pegylation extends the drug's half-life, allowing for once-weekly dosing instead of multiple weekly injections.","oneSentence":"Pegasys is a pegylated interferon alfa-2a that activates innate immune responses to suppress viral replication and inhibit cell proliferation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:05.839Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection"},{"name":"Chronic hepatitis B virus infection"},{"name":"Melanoma (adjuvant therapy)"}]},"trialDetails":[{"nctId":"NCT00006164","phase":"PHASE3","title":"Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2000-06","conditions":"Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver","enrollment":1050},{"nctId":"NCT01679834","phase":"","title":"An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-24","conditions":"Hepatitis C, Chronic","enrollment":7500},{"nctId":"NCT01855997","phase":"","title":"A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-20","conditions":"Hepatitis B, Chronic","enrollment":1669},{"nctId":"NCT00081770","phase":"PHASE3","title":"Peginterferon Dose Evaluations for Previously Untreated Subjects With Chronic Hepatitis C Infected With Genotype 1 (Study P03471)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2004-03","conditions":"Hepatitis C, Chronic","enrollment":4469},{"nctId":"NCT01925183","phase":"PHASE4","title":"Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C","status":"COMPLETED","sponsor":"Markus Peck-Radosavljevic","startDate":"2013-08","conditions":"Hepatitis C, Chronic, HIV","enrollment":6},{"nctId":"NCT01464008","phase":"","title":"The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C","status":"COMPLETED","sponsor":"Beijing Ditan Hospital","startDate":"2004-01","conditions":"Chronic Hepatitis C","enrollment":297},{"nctId":"NCT02690103","phase":"PHASE2","title":"Response Modifier (Arabinoxylan Rice Bran/MGN-3/Biobran) With Interferon-Alpha for HCV","status":"COMPLETED","sponsor":"Cairo University","startDate":"2012-07","conditions":"Hepatitis C, Chronic","enrollment":37},{"nctId":"NCT01471535","phase":"NA","title":"HBsAg Clearance in Inactive Chronic HBsAg Carriers After Interferon Treated","status":"COMPLETED","sponsor":"Beijing Ditan Hospital","startDate":"2008-05","conditions":"Chronic Hepatitis B","enrollment":20},{"nctId":"NCT00502788","phase":"PHASE2","title":"Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)","status":"COMPLETED","sponsor":"Carelon Research","startDate":"2003-05","conditions":"Hepatitis C, Thalassemia","enrollment":21},{"nctId":"NCT01371578","phase":"PHASE2","title":"Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2011-07","conditions":"Hepatitis C, Chronic","enrollment":163},{"nctId":"NCT00800735","phase":"PHASE3","title":"A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-04","conditions":"Hepatitis C, Chronic","enrollment":30},{"nctId":"NCT01892241","phase":"PHASE3","title":"Efficacy and Safety of Peginterferon a-2a in Patients of Chronic Hepatitis B With Spontaneous Decline of HBV DNA","status":"COMPLETED","sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","startDate":"2010-01","conditions":"Antiviral Treatment of Chronic Hepatitis B","enrollment":74},{"nctId":"NCT01853254","phase":"PHASE3","title":"A Study of Pegasys (Peginterferon Alfa-2a) Administered Alone or in Combination With Copegus (Ribavirin) in Patients With Chronic Hepatitis C Who Have Participated in Previous Pegasys Trials","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-09","conditions":"Hepatitis C, Chronic","enrollment":272},{"nctId":"NCT01625793","phase":"NA","title":"Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes","status":"WITHDRAWN","sponsor":"University of Arizona","startDate":"2012-06","conditions":"Hepatitis C","enrollment":""},{"nctId":"NCT01378104","phase":"PHASE4","title":"100% VS 80% Of Pegasys In Koreans With Chronic Hepatitis C (CHC)","status":"COMPLETED","sponsor":"The Catholic University of Korea","startDate":"2008-10","conditions":"Sustained Virologic Response, IL28B Polymorphism","enrollment":178},{"nctId":"NCT00977054","phase":"PHASE4","title":"Double Filtration Plasmapheresis for Hepatitis C Virus (HCV) Genotype 1 Patients With High Viral Load","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2009-09","conditions":"Hepatitis C","enrollment":59},{"nctId":"NCT00917358","phase":"PHASE4","title":"Pegylated Interferon Alfa-2a for Dialysis Patients With Acute Hepatitis C","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2005-07","conditions":"Hepatitis C","enrollment":42},{"nctId":"NCT01596517","phase":"PHASE4","title":"Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2003-06","conditions":"Chronic Hepatitis C","enrollment":272},{"nctId":"NCT00203606","phase":"PHASE4","title":"Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C","status":"COMPLETED","sponsor":"University of Calgary","startDate":"2004-01","conditions":"Hepatitis c","enrollment":66}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":49,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["peginterferon alfa-2a"],"phase":"phase_3","status":"active","brandName":"Pegasys(Roche)","genericName":"Pegasys(Roche)","companyName":"Third Affiliated Hospital, Sun Yat-Sen University","companyId":"third-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pegasys is a pegylated interferon alfa-2a that activates innate immune responses to suppress viral replication and inhibit cell proliferation. Used for Chronic hepatitis C virus infection, Chronic hepatitis B virus infection, Melanoma (adjuvant therapy).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}